Skip to main content
Erschienen in: Pathology & Oncology Research 2/2014

01.04.2014 | Research

Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas of the Gallbladder: An Immunohistochemistry Study of Prognostic Markers

verfasst von: Jiequn Li, Zhu-lin Yang, Qiong Zou, Yuan Yuan, Jinghe Li, Lufeng Liang, Guixiang Zhen, Senlin Chen

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Gallbladder cancers (GBCs) are highly aggressive and lethal diseases. However, the key molecular mechanisms responsible for the progression and prognosis of GBCs have not been identified. No biological markers for effectively identifying GBC subtypes have been reported. In this study the expression of keratin 19 (KRT19) and human achaete-scute homolog 1 (hASH1) proteins in 46 squamous cell/adenosquamous carcinomas (SC/ASC) and 80 adenocarcinomas (AC) were examined using immunohistochemistry. Negative KRT19 or positive hASH1 expression were significantly associated with lymph node metastasis, invasion and TNM stage of SC/ASC patients. In contrast, positive KRT19 and hASH1 expression were significantly associated with large tumor size, lymph metastasis, invasion, and TNM stage in AC patients. Univariate Kaplan–Meier analysis showed that loss of KRT19 or elevated hASH1 expression significantly correlated with decreased survival in SC/ASC patients. In contrast, positive KRT19 and hASH1 expression correlated with a shorter survival time in AC patients. Multivariate Cox regression analysis showed that negative KRT19 expression or positive hASH1 expression was an independent poor-prognostic predictor in SC/ASC, but positive KRT19 and hASH1 expression were poor-prognostic factors in AC patients. Our study suggested that hASH1 can be used to determine the malignancy of SC/ASC and AC tumors and is associated with poor prognosis. In contrast, KRT19 is a protective factor in AC patients but a sign of malignancy in SC/ASC patients.
Literatur
1.
2.
Zurück zum Zitat Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin N Am 39:331–342CrossRef Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin N Am 39:331–342CrossRef
3.
Zurück zum Zitat Bamburg JR, Wiggan OP (2002) ADF/cofilin and actin dynamics in disease. Trends Cell Biol 12:598–605PubMedCrossRef Bamburg JR, Wiggan OP (2002) ADF/cofilin and actin dynamics in disease. Trends Cell Biol 12:598–605PubMedCrossRef
4.
Zurück zum Zitat Roa JC, Tapia O, Cakir A et al (2011) Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol 24:1069–1078PubMedCrossRef Roa JC, Tapia O, Cakir A et al (2011) Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol 24:1069–1078PubMedCrossRef
5.
Zurück zum Zitat Wang W, Eddy R, Condeelis J (2007) The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 7:429–440PubMedCrossRef Wang W, Eddy R, Condeelis J (2007) The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 7:429–440PubMedCrossRef
6.
Zurück zum Zitat Nishihara K, Nagai E, Izumi Y, Yamaguchi K, Tsuneyoshi M (1994) Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res 85:389–399PubMedCrossRef Nishihara K, Nagai E, Izumi Y, Yamaguchi K, Tsuneyoshi M (1994) Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res 85:389–399PubMedCrossRef
7.
Zurück zum Zitat Kondo M, Dono K, Sakon M et al (2002) Adenosquamous carcinoma of the gallbladder. Hepato-Gastroenterology 49:1230–1234PubMed Kondo M, Dono K, Sakon M et al (2002) Adenosquamous carcinoma of the gallbladder. Hepato-Gastroenterology 49:1230–1234PubMed
9.
Zurück zum Zitat Barak V, Goike H, Panaretakis KW, Einarsson R (2004) Clinical utility of cytokeratins as tumor markers. Clin Biochem 37:529–540PubMedCrossRef Barak V, Goike H, Panaretakis KW, Einarsson R (2004) Clinical utility of cytokeratins as tumor markers. Clin Biochem 37:529–540PubMedCrossRef
10.
Zurück zum Zitat Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13:1033–1067PubMedCrossRef Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13:1033–1067PubMedCrossRef
11.
Zurück zum Zitat Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48–57PubMedCrossRef Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48–57PubMedCrossRef
12.
Zurück zum Zitat Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40:403–439PubMedCrossRef Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40:403–439PubMedCrossRef
13.
Zurück zum Zitat Nozato M, Kaneko S, Nakagawara A, Komuro H (2013) Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma. Int J Oncol 42:134–140PubMedCentralPubMed Nozato M, Kaneko S, Nakagawara A, Komuro H (2013) Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma. Int J Oncol 42:134–140PubMedCentralPubMed
14.
Zurück zum Zitat Jain R, Fischer S, Serra S, Chetty R (2010) The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol 18:9–15PubMedCrossRef Jain R, Fischer S, Serra S, Chetty R (2010) The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol 18:9–15PubMedCrossRef
15.
Zurück zum Zitat Axelson H (2004) The Notch signaling cascade in neuroblastoma: role of the basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett 204:171–178PubMedCrossRef Axelson H (2004) The Notch signaling cascade in neuroblastoma: role of the basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett 204:171–178PubMedCrossRef
16.
Zurück zum Zitat Ball DW (2004) Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett 204:159–169PubMedCrossRef Ball DW (2004) Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett 204:159–169PubMedCrossRef
17.
Zurück zum Zitat Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H (2003) The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 134:866–871PubMedCrossRef Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H (2003) The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 134:866–871PubMedCrossRef
18.
Zurück zum Zitat Kunnimalaiyaan M, Traeger K, Chen H (2005) Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 289:G636–G642PubMed Kunnimalaiyaan M, Traeger K, Chen H (2005) Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 289:G636–G642PubMed
19.
Zurück zum Zitat Shida T, Furuya M, Nikaido T et al (2005) Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. Clin Cancer Res 11(2 Pt 1):450–458PubMed Shida T, Furuya M, Nikaido T et al (2005) Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. Clin Cancer Res 11(2 Pt 1):450–458PubMed
20.
Zurück zum Zitat Miki M, Ball DW, Linnoila RI (2012) Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer 75:58–65PubMedCrossRef Miki M, Ball DW, Linnoila RI (2012) Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer 75:58–65PubMedCrossRef
21.
Zurück zum Zitat Jensen-Taubman S, Wang XY, Linnoila RI (2010) Achaete-scute homologue-1 tapers neuroendocrine cell differentiation in lungs after exposure to naphthalene. Toxicol Sci 117:238–248PubMedCentralPubMedCrossRef Jensen-Taubman S, Wang XY, Linnoila RI (2010) Achaete-scute homologue-1 tapers neuroendocrine cell differentiation in lungs after exposure to naphthalene. Toxicol Sci 117:238–248PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Liu DC, Yang ZL (2011) Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 207:472–478PubMedCrossRef Liu DC, Yang ZL (2011) Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 207:472–478PubMedCrossRef
Metadaten
Titel
Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas of the Gallbladder: An Immunohistochemistry Study of Prognostic Markers
verfasst von
Jiequn Li
Zhu-lin Yang
Qiong Zou
Yuan Yuan
Jinghe Li
Lufeng Liang
Guixiang Zhen
Senlin Chen
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2014
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-013-9693-2

Weitere Artikel der Ausgabe 2/2014

Pathology & Oncology Research 2/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.